Moderna stock heads into the open after a near 2% Nasdaq loss
Published on 09/16/2026 at 05:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna stock closed at USD 143.77 on the Nasdaq on September 15, 2026, down about 2.0% from the prior session’s close of USD 146.69 per Nasdaq data cited in recent market summaries. The move left the shares trading between roughly USD 141 and USD 147 during the session while the tech-heavy Nasdaq Composite also ended lower that day, underscoring a weaker backdrop for growth names.
September 15, 2026 in numbers
Moderna Inc. (ISIN US60770K1034, Nasdaq: MRNA) saw its Nasdaq session on September 15, 2026 produce an intraday low of USD 141.16 and last trade at USD 143.77, compared with a prior close of USD 146.69, implying a decline of roughly 2.0% for the day. MarketBeat reported that the stock traded as low as USD 141.16, last traded at USD 143.77, and had previously closed at USD 146.69, highlighting selling pressure versus the earlier level.MarketBeat Against that backdrop, the Nasdaq Composite itself declined on September 15, 2026, with Zacks noting that the index fell 0.6% to close at 26,186.41, so Moderna’s loss modestly outpaced the broader benchmark’s drop.Zacks
Intraday commentary from Eastmoney on the September 15, 2026 United States session described major indices closing lower and noted that Moderna shares fell close to 2% within a mixed performance across pharmaceutical and biotechnology names, indicating that both stock-specific factors and sector sentiment weighed on the price.Eastmoney In addition, MarketBeat linked part of the pressure to insider activity, highlighting that Moderna stock was down about 2% following insider selling disclosures, which kept attention on planned share sales alongside the broader risk-off tone.MarketBeat
Today’s catalysts around September 16, 2026
Looking at potential drivers today, filings cited by StockTitan show that Moderna officer Stephen Hoge submitted a Rule 144 notice for a planned sale of 40,281 shares of common stock in connection with a stock option exercise, with the proposed sale date listed as September 15, 2026, keeping insider transactions in focus around the current trading window.StockTitan Separately, Sina Finance reported that another Moderna insider, James M Mock, disclosed a share sale of company stock dated September 10, 2026 with a transaction amount of roughly USD 1.45 million, adding to the recent stream of insider-related news that investors may continue to monitor as trading resumes today.Sina Finance Broader market attention today is also on United States macroeconomic releases and a Federal Reserve decision highlighted in regional morning notes, which could influence risk appetite for growth and biotechnology stocks such as Moderna depending on how rates and economic expectations shift.Cmoney
